More than half of the world’s pet cats are estimated to be overweight, and a treatment approach resembling Ozempic may soon be tested to help these heavier felines slim down.
Why overweight and obese cats need help
For many owners, getting a beloved cat back to a healthy weight can be a real struggle. Overweight and obese cats are at increased risk of osteoarthritis, hip dysplasia, diabetes mellitus, and cardiovascular problems.
Feline obesity is often linked to free feeding-leaving a full bowl available so cats can eat whenever they like. Tackling excess weight can be challenging, not least because weight loss in cats must be gradual; losing weight too quickly can trigger serious complications such as hepatic lipidosis.
OKAVA Pharmaceuticals’ OKV-119 GLP-1 receptor agonist implant
In a press release, pet drug company OKAVA Pharmaceuticals said its first clinical trial is now under way to assess the safety, tolerability, and efficacy of its drug implant system, OKV-119.
OKAVA’s treatment is intended to be given as an implant placed just beneath the skin. The implant is designed to release medication slowly into the cat’s system for up to six months-potentially far simpler than trying to administer a daily dose to a reluctant pet.
How OKV-119 is intended to work
As with human weight-loss medicines Ozempic and Wegovy, OKAVA’s drug is a GLP-1 receptor agonist. It is designed to imitate the body’s natural satiety hormones and help regulate blood sugar. This receptor is reported to be highly conserved across mammal species, including monotremes.
OKAVA CEO Michael Klotsman noted in a statement that: “Caloric restriction, or fasting, is one of the most well-established interventions for extending lifespan and improving metabolic health in cats, but it’s also one of the hardest to maintain.”
Klotsman also explained that OKV-119 is designed to reproduce several of the physiological effects associated with fasting-such as improved insulin sensitivity, reduced fat mass, and more efficient energy metabolism-without demanding major changes to feeding habits or undermining the human-animal bond that so often revolves around food.
What the trial has (and hasn’t) shown so far
At present, only one cat has received the drug as part of the clinical trials, meaning it is far too early to know whether OKV-119 will ultimately be appropriate for the wider population of overweight cats.
Earlier laboratory studies assessed the system’s safety in healthy cats. In the new trial, researchers will monitor cats closely over 12 weeks, with the goal of determining how effective the drug implant is at helping obese cats return to a healthy weight.
What owners can do in the meantime
Until more evidence is available, experts advise removing kibble between meals rather than leaving food out all day. They also suggest encouraging cats to “hunt” for their food by using enrichment toys, which can slow eating and add activity to a cat’s routine.
It can also help to work with a veterinary team to set a realistic, gradual weight-loss plan-one that avoids rapid changes and reduces the risk of hepatic lipidosis. Weigh-ins, measured portions, and a consistent routine are often more effective than intermittent restrictions that are hard to sustain.
Alongside feeding adjustments, increasing daily movement can make a meaningful difference. Short, frequent play sessions that mimic stalking and pouncing may support weight management while protecting the human-animal bond-especially for cats that have learnt to associate attention primarily with food.
Comments
No comments yet. Be the first to comment!
Leave a Comment